In early October, the FDA said that the shortage of Lilly's Zepbound and Mounjaro, which both contain tirzepatide, was over. That prompted the Outsourcing Facilities Association to file its ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone. “This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor ...

This post hoc analysis of the SURMOUNT-1 study, at 3 years, aimed to assess weight regain from nadir weight over 3 years (36 months / 176 weeks) with tirzepatide treatment. The original SURMOUNT-1 ...